TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16840576

Group type: EXPERIMENTAL
Intervention: Strength training intervention group (3 sessions per week for 13 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Strength training intervention group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (supervised stretching program)
Number of subjects: 26
Study: 14687355

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (1,000 IU/d)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 10879665

Group type: EXPERIMENTAL
Intervention: Polyamide dialyzer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cuprophan dialyzer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Polycarbonate dialyzer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All dialyzers
Number of subjects: 18
Study: 8836309

Group type: EXPERIMENTAL
Intervention: Posatirelin 10 mg/ml, administered intramuscularly once a day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered intramuscularly once a day for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posatirelin 10 mg/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8258839

Group type: EXPERIMENTAL
Intervention: Standard management with systemic hypothermia to 32 to 33 degrees C (n = 24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard management at 37 degrees C (n = 22)
Number of subjects: 46
Study: 3014925

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 16
Study: 30133467

Group type: EXPERIMENTAL
Intervention: Intervention arm (contextualised behavioural intervention strategies)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control arm (general dietary information leaflets)
Number of subjects: 479
Study: 26988650

Group type: EXPERIMENTAL
Intervention: Whole-fat yogurt consumption (quintiles Q1 to Q5)
Number of subjects: 4545

Group type: COMPARATOR
Intervention: Total yogurt consumption
Number of subjects: 4545
Study: 23869755

Group type: EXPERIMENTAL
Intervention: BMS patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 58
Study: 22398313

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (6 fractions per week, 66-68 Gy in 33-34 fractions)
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Conventional radiotherapy (5 fractions per week, 66-68 Gy in 33-34 fractions)
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Both groups (Accelerated and Conventional radiotherapy)
Number of subjects: 1476
Study: 20150531

Group type: EXPERIMENTAL
Intervention: Interactive, cognitive-based and classical stress management exercises and a chat room
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static version of the program including health screening tool, diary and information about stress
Number of subjects: 0
Study: 18313286

Group type: EXPERIMENTAL
Intervention: Remifentanil bolus 0.5 microg/kg before induction followed by a continuous infusion at 0.15 microg x kg(‐1)min(‐1) until peritoneal incision, then restarted after delivery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fentanyl after delivery
Number of subjects: 42
Study: 15699241

Group type: COMPARATOR
Intervention: 15 g alcohol/d (one drink)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 30 g alcohol/d (2 drinks)
Number of subjects: 53
Study: 12447291

Group type: COMPARATOR
Intervention: Propofol sedation guided by conventional monitoring (heart rate, blood pressure, oxygen saturation, electrocardiogram)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol sedation guided by electroencephalogram monitoring displayed online
Number of subjects: 80
Study: 10050562

Group type: EXPERIMENTAL
Intervention: Glucosamine HCl (1,500 mg/day), chondroitin sulfate (1,200 mg/day), and manganese ascorbate (228 mg/day)
Number of subjects: 34
Study: 8587273

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 627
Study: 2200174

Group type: EXPERIMENTAL
Intervention: 50% of maintenance dose of CsA (group 1, n = 27)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Discontinue CsA (group 2, n = 24)
Number of subjects: 51
Study: 90280

Group type: EXPERIMENTAL
Intervention: Various cancer treatments under study
Number of subjects: 0
Study: 30483971

Group type: EXPERIMENTAL
Intervention: Web-based intervention (Suntalk website)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 313
Study: 27765643

Group type: EXPERIMENTAL
Intervention: Prognostic stratified care
Number of subjects: 688

Group type: COMPARATOR
Intervention: Best current care
Number of subjects: 688
Study: 26456905

Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) and elbasvir (50 mg) once daily for 12 weeks
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (deferred treatment group)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Grazoprevir and elbasvir (combined immediate treatment group and intensive pharmacokinetic population)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Grazoprevir and elbasvir (immediate treatment group)
Number of subjects: 224
Study: 23252963

Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg/d at bedtime)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 69
Study: 19926622

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d (group R, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d plus fenofibrate 200 mg/d (group RF, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d plus ezetimibe 10 mg/d (group RE, n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 18067188

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the internal globus pallidus (GPi)
Number of subjects: 69
Study: 17543201

Group type: EXPERIMENTAL
Intervention: Folate and vitamin B12 supplementation
Number of subjects: 0
Study: 12799508

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccination
Number of subjects: 46074

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 46074
Study: 11082471

Group type: EXPERIMENTAL
Intervention: Low socioeconomic status children
Number of subjects: 217

Group type: COMPARATOR
Intervention: High socioeconomic status children
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Children's cortisol levels
Number of subjects: 217
Study: 8675426

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study: 1508357

Group type: EXPERIMENTAL
Intervention: Sodium naproxen 275 mg i.m. administered at the end of surgery and after 12 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sodium naproxen 550 mg i.m. administered at the end of surgery and after 12 hours
Number of subjects: 40
Study: 6379708

Group type: EXPERIMENTAL
Intervention: Exercise tolerance training (weekly attendance and daily home exercises)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exercise at home only (control group)
Number of subjects: 24
Study: 29715296

Group type: EXPERIMENTAL
Intervention: Isomaltodextrin (IMD)
Number of subjects: 0
Study: 26847229

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 41062

Group type: COMPARATOR
Intervention: No decision support system (Control)
Number of subjects: 41062
Study: 25617625

Group type: EXPERIMENTAL
Intervention: Rg1 (5 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 23432159

Group type: EXPERIMENTAL
Intervention: Topical fusidic acid (FA) use
Number of subjects: 185

Group type: COMPARATOR
Intervention: No topical fusidic acid use
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Previous use of topical FA
Number of subjects: 185
Study: 21138714

Group type: EXPERIMENTAL
Intervention: Generic warnings about drinking and driving
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: KYL BAC estimation cards
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Incentives to moderate drinking
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1215
Study: 18442509

Group type: EXPERIMENTAL
Intervention: Eat Well with CF (intervention)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 68
Study: 16526986

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel plus ADT prior to radical prostatectomy
Number of subjects: 0
Study: 12714022

Group type: EXPERIMENTAL
Intervention: Testosterone 60 mg via buccal route
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10920581

Group type: EXPERIMENTAL
Intervention: UVB photochallenge testing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: UVA photochallenge testing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole (TMP‐SMX) usage
Number of subjects: 36
Study: 8617190

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day of zinc as zinc sulfate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study: 1289175

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg daily
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 142
Study: 2982532

Group type: EXPERIMENTAL
Intervention: Pilocarpine stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sweat from patients with cystic fibrosis
Number of subjects: 0
Study: 31102079

Group type: EXPERIMENTAL
Intervention: Poster highlighting the futility of antibiotic treatment for colds
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Poster highlighting the risk of adverse drug reactions from antibiotics
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Poster highlighting the issue of antimicrobial resistance
Number of subjects: 299
Study: 29298160

Group type: EXPERIMENTAL
Intervention: Myeloablative autologous stem-cell transplantation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 75
Study: 27359129

Group type: EXPERIMENTAL
Intervention: Cognitive self-control tasks
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Behavioral self-control tasks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 174

Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 174
Study: 24726247

Group type: COMPARATOR
Intervention: OPV0
Number of subjects: 511
Study: 22152078

Group type: EXPERIMENTAL
Intervention: HI resistance training
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: MI resistance training
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: LI-BFR resistance training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-exercise control group (C)
Number of subjects: 46
Study: 20473861

Group type: EXPERIMENTAL
Intervention: Screening arm (SA) with prostate-specific antigen test every 4 years (cut-off 4.0 ng/ml)
Number of subjects: 80814

Group type: COMPARATOR
Intervention: Control arm (CA) with no interventions
Number of subjects: 80814

Group type: EXPERIMENTAL
Intervention: Screening arm (SA)
Number of subjects: 80814

Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 80814
Study: 18606932

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified maize-soy flour (likuni phala [LP])
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 50 g of fortified spread (FS50)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: 25 g of fortified spread (FS25)
Number of subjects: 182
Study: 16669719

Group type: EXPERIMENTAL
Intervention: Weight management program with olanzapine
Number of subjects: 48
Study: 12816888

Group type: EXPERIMENTAL
Intervention: Autistic group
Number of subjects: 41
Study: 10651837

Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 8692147

Group type: EXPERIMENTAL
Intervention: Mitomycin C (10 mg) given via portal system for intestinal type
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitomycin C (10 mg) given in peritoneal cavity for diffuse type
Number of subjects: 0
Study: 2062515

Group type: EXPERIMENTAL
Intervention: Early photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferral of photocoagulation (control)
Number of subjects: 0
Study: 6851968

Group type: EXPERIMENTAL
Intervention: High dose of norethisterone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low dose of norethisterone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30784422

Group type: EXPERIMENTAL
Intervention: Internet-based intervention (Living Better)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual medical treatment (Control Group)
Number of subjects: 106
Study: 29241359

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 636

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: GG genotype (validation sample)
Number of subjects: 636
Study: 26925867

Group type: EXPERIMENTAL
Intervention: Fluid responsiveness protocol using Non‐Invasive Cardiac Output Monitor (NICOM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 64
Study: 23892504

Group type: EXPERIMENTAL
Intervention: Topical 2 % lidocaine cream
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 64
Study: 22270141

Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HBB) intravenous (i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucagon (GLU) intravenous (i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HBB) intramuscular (i.m.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucagon (GLU) intramuscular (i.m.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined scheme (i.v. GLU + i.m. HBB)
Number of subjects: 6
Study: 19844176

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) 40 mg once daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5000 IU twice daily
Number of subjects: 156
Study: 17077344

Group type: EXPERIMENTAL
Intervention: Cycle exercise for 90 min (67% VO2 peak)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cycle exercise for 20 min (80% VO2 peak)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cycle exercise for 2 min (110% of peak work rate)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cycle exercise for 30 s (maximal sprint)
Number of subjects: 38
Study: 16222402

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg for 5 days and 0.07 g/kg thereafter) with resistance training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo with resistance training
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (creatine and placebo)
Number of subjects: 29
Study: 12174698

Group type: EXPERIMENTAL
Intervention: Bronchial Asthma (BA)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Chronic Obstructive Pulmonary Disease (COPD)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Community-Acquired Pneumonia (CAP)
Number of subjects: 1068
Study: 10208784

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1276
Study: 8703248

Group type: EXPERIMENTAL
Intervention: Budesonide turbuhaler (200 micrograms/dose), two inhalations, twice daily for eight weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo turbuhaler
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Budesonide turbuhaler (200 micrograms/dose)
Number of subjects: 20
Study: 2192717

Group type: EXPERIMENTAL
Intervention: bezafibrate retard plus colestyramine (24 g/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: bezafibrate (400 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: colestyramine plus placebo
Number of subjects: 47
Study: 380773

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31599851

Group type: EXPERIMENTAL
Intervention: Visual analogue scale for pain intensity descriptors
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Presentation order of descriptors
Number of subjects: 248
Study: 30711430

Group type: EXPERIMENTAL
Intervention: Health education by simulation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 27821673

Group type: EXPERIMENTAL
Intervention: Core stability training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional programs
Number of subjects: 32
Study: 25873067

Group type: EXPERIMENTAL
Intervention: Panic Control Treatment
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy
Number of subjects: 216
Study: 23617250

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21896134

Group type: EXPERIMENTAL
Intervention: Pro-Lys-Glu-Lys (PKEK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 19890182

Group type: EXPERIMENTAL
Intervention: Emerging technologies in spine care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional medical therapies models (e.g., quality-adjusted life years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative efforts
Number of subjects: 0
Study: 17048094

Group type: EXPERIMENTAL
Intervention: PECS teaching (15 hours over 4-5 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no PECS teaching)
Number of subjects: 41
Study: 15353006

Group type: EXPERIMENTAL
Intervention: Active interventions
Number of subjects: 3202

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 3202

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3202
Study: 11557913

Group type: EXPERIMENTAL
Intervention: 25 g activated charcoal as a suspension
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25 g activated charcoal as a suspension followed by whole-bowel irrigation with polyethylene glycol (PEG) electrolyte lavage solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: 200 mL water (control)
Number of subjects: 9
Study: 9589857

Group type: EXPERIMENTAL
Intervention: Polymorphism of the angiotensinogen gene in patients with coronary heart disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random sample from the Moscow population
Number of subjects: 0
Study: 8146409

Group type: EXPERIMENTAL
Intervention: 8 mg salbutamol CR twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3292811

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/day for two weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/day for long-term use, average 13.9 months)
Number of subjects: 16
Study: 31515972

Group type: EXPERIMENTAL
Intervention: Once-monthly paliperidone palmitate (PP1M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-every-3-months paliperidone palmitate (PP3M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PP1M/PP3M
Number of subjects: 0
Study: 31434507

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg once daily)
Number of subjects: 3796

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3796
Study: 28288972

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Synthetic disease-modifying antirheumatic drugs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor α
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 25733653

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis at a dose of 10^9 colony-forming units/d
Number of subjects: 727

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study: 24303412

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus dexamethasone (B+D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine (B)
Number of subjects: 60
Study: 21595816

Group type: EXPERIMENTAL
Intervention: Evidence-based education
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 41
Study: 19838972

Group type: EXPERIMENTAL
Intervention: Sequestrectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 100
Study: 16336993

Group type: EXPERIMENTAL
Intervention: Small group education
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Low t-score feedback
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Increased maternal physical activity
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Calcium supplements
Number of subjects: 354

Group type: COMPARATOR
Intervention: Osteoporosis information leaflet
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 354
Study: 14706581

Group type: EXPERIMENTAL
Intervention: Vicryl suture (VS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue adhesive (CTA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Skin tape (ST)
Number of subjects: 48
Study: 11708240

Group type: EXPERIMENTAL
Intervention: FRIENDS program (FGCBT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Self-report measures by children and mothers
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction reported by parents and children
Number of subjects: 71
Study: 9219984

Group type: EXPERIMENTAL
Intervention: Titanium RPDs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cobalt-chromium RPDs
Number of subjects: 20